Drebrin A Biomarker Detection for Early Cognitive Dysfunction Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing cognitive dysfunctions such as Alzheimer's disease are limited to post-mortem pathological analysis or late-stage imaging, lacking early detection capabilities for mild cognitive impairment (MCI).
Innovation Solution
A method for determining cognitive dysfunction stages by measuring the levels of drebrin A or drebrin A-derived molecules, such as DARP, in biological samples like cerebrospinal fluid, combined with amyloid βs and phosphorylated taus, to accurately assess cognitive states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If post-mortem pathological analysis is used to confirm Alzheimer's disease diagnosis, then diagnostic accuracy is improved, but the ability to perform early diagnosis during lifetime is lost
Solution Approach 1:
The invention measures drebrin A levels in biological samples (cerebrospinal fluid, blood, urine, saliva, or lacrimal fluid) to detect cognitive dysfunction before clinical symptoms appear. This preliminary detection enables early intervention and treatment before the disease progresses to late stages, resolving the contradiction between accurate diagnosis and early detection capability
Solution Approach 2:
The invention uses drebrin A as a biomarker intermediary substance that reflects synaptic dysfunction in the brain. By measuring drebrin A levels in easily obtainable biological samples, the invention indirectly detects brain pathology without requiring invasive brain tissue analysis, thus enabling early diagnosis during lifetime while maintaining diagnostic accuracy
2Ease of operation
If question tests or imaging tests are used for lifetime diagnosis, then non-invasive detection is achieved, but early diagnosis of mild cognitive impairment cannot be performed
Solution Approach 1:
The invention replaces subjective question tests and imaging tests with a biochemical measurement system that quantifies drebrin A levels. This substitution provides objective, quantifiable data that can detect mild cognitive impairment earlier and more accurately than traditional methods, while maintaining ease of operation through simple biological sample collection
Solution Approach 2:
The invention introduces a new measurement parameter (drebrin A level) that changes in response to synaptic dysfunction. By monitoring this specific biochemical parameter in biological samples, the invention achieves both early detection of cognitive impairment and objective quantification, overcoming the limitations of traditional question tests and imaging methods
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
An object is to determine a cognitive dysfunction stage of a subject early. The present disclosure provides a method for determining a cognitive dysfunction stage of a subject comprising: a step of measuring a level or amount of at least one of drebrin A or drebrin A-derived molecules in a biological sample collected from the subject; and a step of determining a cognitive dysfunction stage of the subject based on the level or amount.